ImpactAlpha, July 8 — The Series A financing will help VitriVax commercialize ALTA, its protective coating to extend the shelf life of vaccines without refrigeration or freezing.
The Boulder, Colo.-based biotech is working with vaccine providers to deliver animal and human vaccines in underserved countries. “Adjuvant Capital has canvassed the globe for vaccine platforms like ALTA,” said Adjuvant’s Charlie Petty, who along with Glenn Rockman will join VitriVax’s board of directors.
Global health mission
Adjuvant Capital combines catalytic and commercial capital to finance the development of drugs, vaccines, diagnostics and medical devices for diseases such as malaria, shigella, hookworm, HIV and tuberculosis in low- and middle-income countries (see, “Investors put $300 million into Adjuvant Capital as global health innovation shines”).